FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso, Proxofim
FOXO4-DRI is an experimental senolytic peptide studied mostly in animals for its reported ability to selectively clear senescent ('aged') cells. It is not approved for human use, and human dosing has not been established.
- Category
- Longevity / Anti-Aging
- Reported half-life
- Not established in humans
- Common forms
- Lyophilised powder for reconstitution (research), Reconstituted injectable solution (research/grey-market)
- Research status
- Experimental senolytic peptide; NOT approved for human use. Evidence is mostly preclinical (cell and animal data), and human safety, dosing and effectiveness are not established.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in animal studies to be associated with clearance of senescent cells
- Reported in preclinical work to influence markers linked to tissue ageing
- Users and researchers report interest in longevity and healthspan contexts, though human data is absent
- Reported to disrupt a FOXO4-p53 interaction inside senescent cells
How it is reported to work
FOXO4-DRI is a D-retro-inverso peptide reported to interfere with the interaction between the FOXO4 protein and p53 inside senescent cells. By disrupting this binding, it is proposed to push senescent cells toward programmed cell death (apoptosis) while sparing healthy cells. These mechanisms come almost entirely from cell and animal research and are considered experimental.
What is FOXO4-DRI?
FOXO4-DRI is an experimental senolytic peptide designed to selectively clear senescent (“worn-out”) cells, studied mostly in animals and not approved for human use anywhere. The name refers to its “D-retro-inverso” design, a modification intended to make the peptide more stable. Human dosing has not been established, and it is sometimes marketed under the research name Proxofim. This page is educational information, not medical advice, and every effect below is a reported claim drawn largely from preclinical research, not an established fact.
How does FOXO4-DRI work?
It is reported to disrupt the FOXO4-p53 interaction inside senescent cells. By interfering with this binding, it is proposed to push those aged cells toward programmed death (apoptosis) while sparing healthy cells. This is an experimental, cell- and animal-derived mechanism and should not be treated as proven in humans.
What does the research show?
Almost all evidence comes from laboratory and animal work rather than human trials.
| Evidence type | Status |
|---|---|
| Laboratory (in vitro) studies | Present |
| Animal studies | Present |
| Human clinical trials | Absent |
| Australian medicine approval | Not approved |
Because there are no human trials, any reported human “benefit” is anecdotal and unverified.
What do people use it for (reported)?
FOXO4-DRI is reported to be of interest in longevity and healthspan contexts, based on animal senescent-cell findings. These are reported research interests, not validated outcomes, and nothing here encourages use.
Is FOXO4-DRI safe?
Its safety in humans is unknown. There are no human trials, senolytic effects could carry serious unstudied risks, and grey-market peptide cannot be verified for purity or identity by consumers. Reported side effects from self-experimentation include injection-site reactions, fatigue and flu-like feelings, but the more important concern is the complete absence of long-term human safety data. Because purity and vial content cannot be confirmed by sight, independent testing is often discussed in the research community for compounds like this. This article explains what FOXO4-DRI is; it does not recommend obtaining or using it, and all effects described remain reported claims. Anyone with health or ageing concerns should consult a qualified healthcare professional.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in animal studies to be associated with senescent-cell clearance
- Reported interest as a targeted (senolytic) approach in research contexts
- Reported in preclinical work to spare healthy cells while acting on senescent ones
- Reported focus of ongoing longevity research discussion
Common side effects
- Reported injection-site reactions
- Reported fatigue or malaise after dosing
- Reported flu-like feelings in some users
- Reported nausea
Rare / serious side effects
- Unknown serious risks given the absence of human trials
- Reported reactions to contaminated or mislabelled grey-market peptide
- Potential for unintended cell-death effects beyond senescent cells (theoretical)
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of FOXO4-DRI. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-experimentation with injectable doses despite no established human dosing
- Reported frequent or continuous dosing rather than the intermittent pattern seen in animal studies
- Reported dosing errors from unverified reconstitution and unknown vial content
- Reported stacking with other experimental compounds, compounding unknown risks
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. There is no validated human onset; in animal studies effects are reported over days to weeks of intermittent dosing, but human timing is unknown.
First effects
No validated human onset; animal effects reported over days to weeks
Reported window
Preclinical effects described over a few weeks of intermittent dosing
Longer term
Any human effects are unstudied over longer periods
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take FOXO4-DRI. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous or intraperitoneal injection (research); human route not established |
|---|---|
| Typical reported dose | Human dosing NOT established; animal studies used intermittent pulsed dosing only |
| Frequency | Reported intermittent/pulsed pattern in animal studies (e.g. a few doses per cycle), not daily |
| Cycle length | Reported as short intermittent cycles in preclinical work; no validated human cycle |
Reported reconstitution (mg → units)
Example only (not a recommendation): a 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL (10 ÷ 2 = 5). A hypothetical 2.5 mg amount would be 0.5 mL = 50 units on a U-100 insulin syringe (2.5 ÷ 5 = 0.5 mL; 0.5 × 100 = 50 units). Because human dosing is not established, this is arithmetic illustration only.
Work out the units for your vial → CalculatorReported community use mirrors the intermittent, pulsed dosing pattern used in animal studies rather than continuous daily use, but no human cycle has been validated. These are reported patterns only and not a recommendation; human dosing is not established.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
FOXO4-DRI is an experimental research peptide and is not approved for human use anywhere. There are no human trials establishing its safety, and grey-market products cannot be verified for purity or identity. Senolytic mechanisms could carry serious unknown risks. This page is educational and is not medical advice; anyone with health or ageing concerns should consult a qualified healthcare professional.